Smith & Nephew (LON:SN) PT Raised to GBX 1,381

Smith & Nephew (LON:SN) had its price target upped by investment analysts at JPMorgan Chase & Co. from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) in a research note issued on Thursday, MarketBeat.com reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 38.54% from the stock’s previous close.

SN has been the topic of a number of other reports. Barclays reissued an “equal weight” rating and set a GBX 1,150 ($14.45) price target on shares of Smith & Nephew in a research report on Friday, February 9th. Berenberg Bank reissued a “buy” rating and set a GBX 1,450 ($18.21) target price on shares of Smith & Nephew in a research report on Thursday. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a GBX 1,500 ($18.84) target price on shares of Smith & Nephew in a report on Friday, April 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 1,346.20 ($16.91).

Smith & Nephew Trading Up 1.1 %

LON SN opened at GBX 996.80 ($12.52) on Thursday. The company has a current ratio of 1.77, a quick ratio of 0.84 and a debt-to-equity ratio of 59.11. The business has a fifty day simple moving average of GBX 1,021.40 and a 200 day simple moving average of GBX 1,034.26. Smith & Nephew has a 12 month low of GBX 887 ($11.14) and a 12 month high of GBX 1,316.75 ($16.54). The firm has a market capitalization of £8.72 billion, a P/E ratio of 4,106.67, a PEG ratio of 0.46 and a beta of 0.51.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.